Mesoblast Limited
Mesoblast Limited (MESO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · MESO · as of Jun 8, 2026
Key Statistics
Explore Mesoblast Limited Data
meso stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 11 · Buy rate: 45.5%
The MESO analyst consensus is Buy, based on ratings from 11 Wall Street analysts over the past 3 months. The average 12-month price target is $11.50, representing -17.27% downside from the current price of $13.90.
Competitors & Peers
meso competitorsMESO
COGT
EWTX
GLPG
GPCR
IBRXStock Performance
Full HistoryAbout Mesoblast Limited
Mesoblast Limited a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company o…
what is mesoblast limited · meso stock overview · mesoblast limited company profile · who is mesoblast limited ceo · meso NASDAQ · mesoblast limited headquarters · mesoblast limited business segments
About Stock Overview & Key Data
Mesoblast Limited (MESO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 20, 2010. As of the latest trading session, MESO stock price is $13.90, with a market capitalization of $1.8B. The stock has returned +17.30% over the past 12 months and -22.95% year-to-date.
According to 11 Wall Street analysts, the consensus rating for Mesoblast Limited stock is Buy, with an average 12-month price target of $11.50. In fiscal year 2025, Mesoblast Limited reported revenue of $17.2M and net income of -$102.1M. For detailed data — including Mesoblast Limited revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Mesoblast Limited (MESO) stock price is $13.90. The stock is traded on NASDAQ under the ticker symbol MESO. The 52-week range is $9.88 – $21.50.